JGC
APGE

J. Goldman & Co’s Apogee Therapeutics APGE Stock Holding History

J. Goldman & Co’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,466
Closed -$262K – 659
2025
Q4 		$262K Sell
3,466
-59,111
-94% -$3.72M 0.01% 499
2025
Q3 		$2.49M Buy
62,577
+27,972
+81% +$1.07M 0.06% 264
2025
Q2 		$1.5M Buy
+34,605
New +$1.32M 0.04% 309

Other funds holding APGE

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

J. Goldman & Co's APGE Position: Q1 2026 in Review

J. Goldman & Co sold out of Apogee Therapeutics (APGE) in Q1 2026, closing a stake of 3,466 shares — an estimated $262K sold.

J. Goldman & Co first reported a position in APGE in Q2 2025 and held it in 3 quarters. The position peaked at $2.49M in Q3 2025. 224 funds tracked by Wall St. Rank hold APGE as of Q1 2026.

  • J. Goldman & Co reported no remaining Apogee Therapeutics position as of Q1 2026 after selling out during the quarter.
  • J. Goldman & Co sold 3,466 Apogee Therapeutics shares in Q1 2026, an estimated $262K.
  • J. Goldman & Co first reported a position in Apogee Therapeutics in Q2 2025 and held it in 3 quarters.
  • J. Goldman & Co's Apogee Therapeutics position peaked at $2.49M in Q3 2025.
  • 224 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q1 2026.

Based on J. Goldman & Co's 13F filing for Q1 2026, filed 15 May 2026.